Filing Details

Accession Number:
0001140361-14-046759
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-30 19:37:27
Reporting Period:
2014-12-26
Filing Date:
2014-12-30
Accepted Time:
2014-12-30 19:37:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1302573 Oncomed Pharmaceuticals Inc OMED Pharmaceutical Preparations (2834) 383572512
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1297000 Denise Pollard-Knight C/O Oncomed Pharmaceuticals, Inc.
800 Chesapeake Drive
Redwood City CA 94063
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-12-26 2,195 $21.65 1,962,720 No 4 S Indirect See Footnote
Common Stock Disposition 2014-12-29 9,902 $21.62 1,952,818 No 4 S Indirect See Footnote
Common Stock Disposition 2014-12-30 5,510 $21.65 1,947,308 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. This transaction was executed in multiple trades in prices ranging from $21.60 to $21.72, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  2. The shares of common stock of OMED are owned by Phase4 Ventures III LP ("Phase4"). The Reporting Person is a partner of Phase4 Partners Limited, which is the manager of Phase4. The Reporting Person disclaims beneficial ownership of the reported securities held by Phase4 except to the extent of her pecuniary interest therein.
  3. This transaction was executed in multiple trades in prices ranging from $21.60 to $21.65, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. This transaction was executed in multiple trades in prices ranging from $21.60 to $21.78, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.